We dont know how the prices of novel GLP-1s will change, we dont know what new GLP-1s will be introduced, we dont know how many generics there will be, we dont know how many people will ultimately use them, we dont know how long people will stay on them, we dont know what Medicare drug price negotiations will do to the price, and we dont even know if reducing obesity impacts long-term health spending
GLP-1 medications can be helpful for many patients, but they are not the right long-term answer for everyone
Abstract Tirzepatide is the first dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes in adults, for reducing excess body weight and maintaining long-term weight reduction in adults with obesity or overweight and at least one weight-related comorbid condition, and for treating obstructive sleep apnea in adults with obesity
For those who maintained consistent GLP-1 use, medical cost growth was six to nine percentage points lower compared to non-users, and female GLP-1 users saw a 47% reduction in hospitalizations for major cardiovascular events
